{
    "id": 9156,
    "fullName": "ARID1A mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ARID1A mutant indicates an unspecified mutation in the ARID1A gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 8289,
        "geneSymbol": "ARID1A",
        "terms": [
            "ARID1A",
            "B120",
            "BAF250",
            "BAF250a",
            "BM029",
            "C1orf4",
            "CSS2",
            "ELD",
            "hELD",
            "hOSA1",
            "MRD14",
            "OSA1",
            "P270",
            "SMARCF1"
        ]
    },
    "variant": "mutant",
    "createDate": "07/16/2015",
    "updateDate": "09/07/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8053,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) resulted in decreased cell growth of ovarian clear cell carcinoma (OCCC) cells harboring an ARID1A mutation in culture and anti-tumor activity in cell line xenograft models of OCCC (PMID: 27364904).",
            "molecularProfile": {
                "id": 9069,
                "profileName": "ARID1A mutant"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 50934,
                "name": "ovarian clear cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6543,
                    "pubMedId": 27364904,
                    "title": "Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27364904"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11895,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VX-970 treatment in ovarian clear cell carcinoma cells harboring an ARID1A mutation resulted in decreased cell survival and induction of DNA damage and apoptosis in culture, and tumor growth inhibition in cell line xenograft models (PMID: 27958275).",
            "molecularProfile": {
                "id": 9069,
                "profileName": "ARID1A mutant"
            },
            "therapy": {
                "id": 2879,
                "therapyName": "VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 50934,
                "name": "ovarian clear cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9887,
                    "pubMedId": 27958275,
                    "title": "ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27958275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3228,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UNC1999 inhibited growth of ovarian cancer cell lines harboring ARID1A mutations in culture (PMID: 25686104).",
            "molecularProfile": {
                "id": 9069,
                "profileName": "ARID1A mutant"
            },
            "therapy": {
                "id": 1757,
                "therapyName": "UNC1999",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3263,
                    "pubMedId": 25686104,
                    "title": "Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25686104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8459,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, 100% (5/5) of renal cell carcinoma patients harboring ARID1A mutations achieved the primary endpoint of 6 month PFS when treated with the combination therapy Afinitor (everolimus) and Avastin (bevacizumab) (PMID: 27601542).",
            "molecularProfile": {
                "id": 9069,
                "profileName": "ARID1A mutant"
            },
            "therapy": {
                "id": 1120,
                "therapyName": "Bevacizumab + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6663,
                    "pubMedId": 27601542,
                    "title": "Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27601542"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11889,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian clear cell carcinoma cells harboring an ARID1A mutation were sensitive to VE-821 in in vitro assays, demonstrating decreased cell survival (PMID: 27958275).",
            "molecularProfile": {
                "id": 9069,
                "profileName": "ARID1A mutant"
            },
            "therapy": {
                "id": 2877,
                "therapyName": "VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 50934,
                "name": "ovarian clear cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9887,
                    "pubMedId": 27958275,
                    "title": "ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27958275"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2544,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 selectively inhibited growth of ARID1A-mutant ovarian cancer cells in culture, and induced tumor regression in ARID1A-mutant ovarian cancer xenograft models (PMID: 25686104).",
            "molecularProfile": {
                "id": 9069,
                "profileName": "ARID1A mutant"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3263,
                    "pubMedId": 25686104,
                    "title": "Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25686104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3230,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of PIK3IP1 expression resulted in decreased growth inhibition by GSK126 in ARID1A-mutant ovarian cancer cells in culture (PMID: 25686104).",
            "molecularProfile": {
                "id": 28922,
                "profileName": "ARID1A mut PIK3IP1 dec exp"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3263,
                    "pubMedId": 25686104,
                    "title": "Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25686104"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3229,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of a constitutively active PIK3CA mutation in ARID1A-mutant ovarian cancer cell lines enhanced growth inhibition by GSK126 in culture (PMID: 25686104).",
            "molecularProfile": {
                "id": 28923,
                "profileName": "ARID1A mut PIK3CA act mut"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3263,
                    "pubMedId": 25686104,
                    "title": "Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25686104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 9069,
            "profileName": "ARID1A mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28922,
            "profileName": "ARID1A mut PIK3IP1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28923,
            "profileName": "ARID1A mut PIK3CA act mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}